# THERAPY-HYBRID-BPA Trial

> **NCT04600492** · PHASE2 · UNKNOWN · sponsor: **National Hospital Organization Okayama Medical Center** · enrollment: 72 (estimated)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Riociguat Oral Tablet

## Key facts

- **NCT ID:** NCT04600492
- **Lead sponsor:** National Hospital Organization Okayama Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-16
- **Primary completion:** 2023-09-30
- **Final completion:** 2025-01-28
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2020-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600492, "THERAPY-HYBRID-BPA Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04600492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*